Targeting an epigenetic enzyme to enhance chemotherapy response in high-grade serous ovarian cancers

Project summary

Project
Ovarian cancer patients currently have little to no-curative options highlighting an unmet clinical need. To address this issue, we performed a genetic screen to identify factors that synergize with available therapeutic options to effectively kill ovarian cancer cells. We have identified an epigenetic enzyme which when depleted, significantly increases the sensitivity of ovarian cancer lines to platinum and PARP inhibitors. Here, we will examine the underlying mechanism of this phenotype and extend our findings to mouse- and patient models. Given that an inhibitor for this enzyme is in clinical trial, we hope that our findings can be readily translated.

This grant was made possible by a generous donation made in memory of Susan (Simcha) Rudolph.